Skip to main content

Safe and effective preventative Epstein-Barr Virus (EBV) vaccine

Ref-Nr: TA-P-1309


Kurzfassung

This invention provides a safe Epstein-Barr Virus vaccine, which does not introduce chromosomal instabilities associated with cancer development.


Hintergrund

Experts estimate that an EBV vaccine could prevent 2% of all cancer cases worldwide.


Problemstellung

Until now no method for producing a safe and efficient vaccine against EBV has been devel-oped.


Lösung

This vaccine uses “virus-like particles” (VLP), devoid of detectable genetic material, to mimic an EBV infectious particle. While these particles prompt the body to mount an immune response they are themselves innoc-uous, thus making the vaccine much safer.


Vorteile

This vaccine lacks the ability of EBV particles to induce chromosome instability and chromo-somal associated with cancer development. In particular, EBV particles in this vaccine do not enter the cytosol and/or nucleus of cells, mak-ing it significantly safer than existing alterna-tives.


Anwendungsbereiche

Prevention from EBV disease


Service

Convincing in vitro and in vivo data are avail-able showing the absence of chromosomal instability after treatment with the new genera-tion VLP. Animal studies looking at safety and efficacy of the VLPs are currently being con-ducted.


Deutsches Krebsforschungszentrum DKFZ

Dr. Frieder Kern
+49-6221-42-2952
f.kern@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Machbarkeit


Stichworte

Vaccines

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr